Loading...
Loading...
Immunomedics, Inc.,
today announced that sacituzumab govitecan, the Company's novel
investigational antibody-drug conjugate (ADC), continues to produce a partial
response (PR) rate of 30% and a 70% clinical benefit rate (CBR), defined as PR
and stable disease, in patients with metastatic triple-negative breast cancer
(TNBC) who had been heavily pretreated. For patients with PR or stable disease
longer than 6 months, the CBR was 40%. Significantly, PRs ranging from 30% to
70% tumor shrinkage as best response were reported. Responses are measured by
computed tomography (CT) based on RECIST 1.1 criteria.
Dr. Aditya Bardia of Massachusetts General Hospital Cancer Center, Harvard
Medical School, Boston, MA, presented the Phase 1/2 study at the San Antonio
Breast Cancer Symposium in San Antonio, TX. Commenting on the results, Dr.
Bardia stated, "TNBC patients in this late-stage setting have limited
treatment options that are effective. We are quite encouraged with this
experience with sacituzumab govitecan, especially the time-to-progression
results, which showed that the duration of response for the responding
patients was generally longer than their last prior therapy for TNBC."
As the name implies, TNBC represents breast cancers that are negative for
estrogen and progesterone receptors, as well as human epidermal growth factor
receptor 2, or HER2. This type of breast cancer comprises about 15-20% of all
invasive breast cancers and is more prevalent in young and African-American
women. Despite the fact that initial responses with chemotherapy are high,
TNBC characteristically has a high recurrence rate and is perhaps the most
difficult type of breast cancer to treat successfully with current cytotoxic
agents. According to a published report, the median survival for patients with
metastatic triple-negative breast cancer is estimated to be 13 months.^1
Currently, there are no targeted treatments available for TNBC.
More than 40 patients with relapsed or refractory metastatic TNBC have been
enrolled into the multicenter study, of which 23 patients were evaluable with
at least one post-therapy CT assessment. These patients had a median of 4
prior therapies (range 1-15) with taxane, a FDA-approved drug for breast
cancer treatment, alone or in combination with other chemotherapeutic agents
or investigational drugs.
The adverse event profiles for 21 patients were available at the time of
reporting. Transient neutropenia (9 patients) was the major Grade 3 or 4
toxicity, while manageable diarrhea (11 patients) was the main Grade 1 or 2
event. No patient discontinued therapy due to toxicity.
"After we have completed patient enrollment into this study, which is expected
by the end of this month, we plan to discuss the registration pathway for this
valuable agent in breast cancer with FDA and our medical advisers," remarked
Cynthia L. Sullivan, President and Chief Executive Officer. "Furthermore,
discussions with potential corporate partners are ongoing," Ms. Sullivan
added.
In addition to Dr. Bardia of Massachusetts General Hospital, the multicenter
study also involved Dr. Alexander Starodub, Indiana University Health Center
for Cancer Care, Goshen, IN; Dr. Rebecca L. Moroose, UF Health Cancer Center,
Orlando, FL; Dr. Ingrid A. Mayer, Breast Cancer Program, Vanderbilt-Ingram
Cancer Center, Vanderbilt University, Nashville, TN; Dr. Jennifer R. Diamond,
University of Colorado Cancer Center, Aurora, CO; Drs. Ellen Chuang, Allyson
J. Ocean, and Linda T. Vahdat, Weill Cornell Medical College, New York, NY.
In a separate presentation at this year's Symposium, Dr. David M. Goldenberg,
Chief Scientific Officer, described the Company's ADC technology, which uses a
moderately-toxic drug, SN-38, the active metabolite of irinotecan, conjugated
to an anti-TROP-2 antibody at a drug to antibody ratio of 7.6, which is about
twice that of other ADCs, for the creation of sacituzumab govitecan.
With the use of a moderately-toxic drug, patients were able to tolerate a
dosing schedule of once a week for two weeks followed by one week of rest in a
3-week cycle, which increases the therapeutic index of the ADC. Indeed,
sacituzumab govitecan has also demonstrated activity in other solid tumors,
producing PRs in patients with colorectal, esophageal, small-cell and
non-small-cell lung, and urinary bladder cancers. Despite repeated dosing, no
antibodies against the ADC, either to the antibody or to the SN-38, have been
detected.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in